Impact of zoledronic acid on control of metastatic spinal cord compression

Strahlentherapie und Onkologie

Volumn 188, Issue 10, 2012, Pages 910-916

  Rades, D ^a   Hakim, S G ^a   Bajrovic, A ^b   Karstens, J H ^c   Veninga, T ^d   Rudat, V ^e   Schild, S E ^f  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d DR BERNARD VERBEETEN INSTITUTE   (Netherlands)

^e Saad Specialist Hospital Al Khobar   (Netherlands)

^f MAYO CLINIC   (United States)

Author keywords

Local control; Metastatic spinal cord compression; Radiotherapy; Treatment outcomes; Zoledronic acid

Indexed keywords

CALCIUM; DEXAMETHASONE; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CREATININE CLEARANCE; FEMALE; FOLLOW UP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; METASTATIC SPINAL CORD COMPRESSION; MOTOR PERFORMANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PSYCHOMOTOR DISORDER; RADIATION DOSE; RETROSPECTIVE STUDY; SPINAL CORD METASTASIS; SURVIVAL RATE; THORACIC SPINE;

AGED; BONE DENSITY CONSERVATION AGENTS; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; DIPHOSPHONATES; FEMALE; GERMANY; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PREVALENCE; RADIOTHERAPY, CONFORMAL; RISK FACTORS; SPINAL CORD COMPRESSION; SPINAL NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84866709172     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-012-0158-4     Document Type: Article

References (8)

1. Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
2. Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321
3. Rades D, Lange M, Veninga T et al (2011) Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 79:524-530
4. Rosen LS, Gordon DH, Dugan W et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36-43
5. Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase II, double-blind, randomized trial - The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157
6. Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
7. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882
8. Van Poznak CH, Temin S, Yee GC et al (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221-1227